Tag: Biotech and Pharma

Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to Zealand Pharma in a licensing and development agreement.

Novo Nordisk shares fell after the pharmaceutical giant released fresh trial results for its CagriSema developmental weight-loss drug.

Amgen on Wednesday said it has started two critical late-stage trials for its experimental weight loss injection MariTide, another step in its bid to enter the booming obesity drug market. 

Novo Nordisk on Wednesday said it will offer its weight loss drug Wegovy for less than half of its usual price per month through a new direct-to-consumer online pharmacy.

Shares of vaccine maker Moderna dropped more than 5% late Wednesday after reports that the Health and Human Services Department was re-evaluating its $590 million contract to develop a bird flu vaccine.

Novavax stock is rising after the vaccine maker posted quarterly results above analysts expectations early Thursday.

Eli Lilly said on Tuesday it has begun selling higher doses of its popular weight-loss drug Zepbound in vials in the U.S. at a $150 discount to the cost of the injector pen versions, as it seeks to spur demand for the medicine.

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer.

Στον δείκτη υψηλής κεφαλαιοποίησης Large Cap του FTSE Russell εισέρχεται η μετοχή της ΓΕΚ ΤΕΡΝΑ, μετά την αναδιάρθρωση των δεικτών την Παρασκευή 21 Φεβρουαρίου στο πλαίσιο της τριμηνιαίας αναθεώρησης του οίκου.

U.S. President Donald Trump said on Tuesday he intends to impose auto tariffs “in the neighborhood of 25%” and similar duties on semiconductors and pharmaceutical imports, the latest in a series of measures threatening to upend international trade.

Johnson & Johnson faces a critical test on Tuesday over its $10 billion proposal to end litigation alleging that its baby powder caused ovarian cancer, as it tries to convince a judge to sign off on its third attempt to resolve thousands of lawsuits through a subsidiary’s bankruptcy.

Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to scale down manufacturing amid weakening demand for its COVID-19 vaccine.

UK drugmaker AstraZeneca overcame a drop in sales in China and the arrest of its top executive in the country to deliver an 18 per cent increase in revenues in the final quarter of 2024.

Bristol Myers Squibb on Thursday said it will slash $2 billion in costs by the end of 2027, expanding its ongoing cost savings effort to chart a path toward long-term growth.

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, providing some relief to investors after another quarter of sales miss for its popular diabetes and weight-loss treatments.

GSK plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments.

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t its wildly popular weight-loss drugs.

Shares of vaccine companies fell on Tuesday after a Senate panel voted to advance Robert F. Kennedy Jr.’s nomination to lead the Department of Health and Human Services to the full chamber. 

Merck said it will pause shipments of Gardasil to China through at least mid-year, as continued weak demand for the HPV vaccine there is expected to hurt 2025 revenue, but it still posted a strong fourth-quarter profit on sales of cancer drug Keytruda.

Drugmaker Pfizer posted a better than expected fourth quarter profit on Thursday, helped by cost cuts and a smaller-than-feared drop in sales of its COVID-19 vaccine.